PharmaVoice

Pharma Tech

Ferring bets on Gameto’s reproductive health solution through $1.38bn takeover

Gameto’s lead asset is a cell-based IVM tool, Fertilo, which is currently in late-stage development within the US.

Pharma Tech

IDWeek 2026: despite missing primary endpoint, LB6V shows promise in Lyme disease

The commercial opportunity for a prophylactic Lyme disease vaccine in the US and Europe is substantial. LB6V is well placed to capitalise on this gap.

Read Full Article

Pharma Tech

Astellas fortifies immuno-oncology pipeline on $1.3bn Audax licensing deal

Astellas pens this immuno-oncology deal with Audax as it looks to offset the upcoming patent expiry of key portfolio medicine, Xtandi.

Read Full Article

Pharma Tech

Anthropic plots IPO amid ongoing foray into drug development

Anthropic hopes Powerful AI will “match or exceed the cognitive capabilities of top human experts across scientific disciplines”.

Read Full Article

Pharma Tech

FDA grants orphan drug status to Octant’s OCT-980 for RP

The FDA has granted orphan drug designation to Octant’s OCT-980, an investigational oral small molecule, to treat retinitis pigmentosa.

Read Full Article

Featured promotional

Jeplus.in

Purchase All Medicines.Get 10% Offer

News

Latest stories

Pharma Tech

Oct 28, 2026, 4:13 PM

Ferring bets on Gameto’s reproductive health solution through $1.38bn takeover

Gameto’s lead asset is a cell-based IVM tool, Fertilo, which is currently in late-stage development within the US.

Read

Pharma Tech

Oct 28, 2026, 2:00 PM

IDWeek 2026: despite missing primary endpoint, LB6V shows promise in Lyme disease

The commercial opportunity for a prophylactic Lyme disease vaccine in the US and Europe is substantial. LB6V is well placed to capitalise on this gap.

Read

PharmaShots

Oct 28, 2026, 12:03 PM

Cullinan Therapeutics Receives the US FDA’s IND Clearance for Velinotamig to Treat ITP and wAIHA

Shots: Cullinan Therapeutics has received IND clearance from the US FDA & clearance from Australia’s TGA to initiate a global P-Ib/IIa trial of velinotamig (CLN-803), a SC BCMAxCD3 T-cell engager, in adults with R/R immune thrombocytopenia (ITP) & warm autoimmune hemolytic anemia (wAIHA) The open-label, multicenter trial (NCT07738822) will evaluate a defined course of 4… The post Cullinan Therapeutics Receives the US FDA’s IND Clearance for Velinotamig to Treat ITP and wAIHA appeared first on PharmaShots.

Read

PharmaShots

Oct 28, 2026, 12:00 PM

Arrowhead Receives the UK MHRA’s Approval and NICE Recommendation for Redemplo (Plozasiran) to Treat Familial Chylomicronaemia Syndrome

Shots: The UK MHRA has granted marketing authorisation to Arrowhead Pharmaceuticals’ Redemplo (plozasiran) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronaemia syndrome (FCS), diagnosed via genetic testing or clinical criteria NICE has also issued guidance recommending NHS funding in England & Wales for adults with genetically confirmed FCS whose response… The post Arrowhead Receives the UK MHRA’s Approval and NICE Recommendation for Redemplo (Plozasiran) to Treat Familial Chylomicronaemia Syndrome appeared first on PharmaShots.

Read

PharmaShots

Oct 28, 2026, 11:49 AM

US WorldMeds Acquires Orbus Therapeutics to Advance Eflornithine in Adult Malignant Glioma

Shots: US WorldMeds has acquired Orbus Therapeutics, adding its late-stage oral eflornithine (DFMO) program for recurrent Grade 3 astrocytoma; Orbus is now a wholly owned subsidiary of US WorldMeds US WorldMeds made an undisclosed upfront payment, with Orbus eligible for development, regulatory & sales milestones, plus tiered royalties on US net sales The P-III (STELLAR)… The post US WorldMeds Acquires Orbus Therapeutics to Advance Eflornithine in Adult Malignant Glioma appeared first on PharmaShots.

Read

PharmaShots

Oct 28, 2026, 11:21 AM

Idorsia Initiates P-III (FAB-KLEAR) Trial of Lucerastat for Fabry Disease and Partners with Nxera for Japan and APAC

Shots: Idorsia has initiated the pivotal P-III (FAB-KLEAR) kidney biopsy trial of lucerastat, an oral substrate reduction therapy, in 16 treatment-naïve or pseudo-naïve adult male pts with Fabry disease, assessing change in kidney Gb3 BLISS score at Mos. 18 as its 1EP The P-III program also includes the 74-pt FAB-SWITCH trial vs SoC ERTs; both… The post Idorsia Initiates P-III (FAB-KLEAR) Trial of Lucerastat for Fabry Disease and Partners with Nxera for Japan and APAC appeared first on PharmaShots.

Read

News